Aripiprazole
Product Images NDC 68071-2708

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-2708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2708 3)

Aripiprazole 10mg tablets packaging label from NuCare Pharmaceuticals, Inc. The label shows 30 tablets and includes the NDC 68071-2708-3. Manufactured by Alkem Laboratories Ltd., Mumbai, India. The label contains product and lot information, barcode, and storage instructions.*

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier survival curve chart depicting the proportion of subjects with relapse over days from randomization. Two groups are compared: Aripiprazole and Placebo. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk at different time points for both groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization. The chart compares two groups: one treated with Aripiprazole and a placebo group. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse, including the number of subjects at risk at various time points for both groups.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing the fold change and 90% confidence intervals for Dehydro-Aripiprazole levels influenced by various inhibitors and other drugs. The chart compares changes in AUC and Cmax relative to a reference without interacting drug, including CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other medications such as valproate, lithium, and lorazepam.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A chart depicting fold changes with 90% confidence intervals for various drugs and pharmacokinetic (PK) parameters, including clearance (CL), area under the curve (AUC), and maximum concentration (Cmax). The x-axis represents change relative to a reference without interaction, ranging from 0.5 to 3.0, while the y-axis lists drugs and enzymes such as CYP2D6, CYP2C9, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic (PK) chart showing Aripiprazole fold change and 90% confidence intervals (CI) for various factors affecting drug metabolism. The chart compares AUC and Cmax values for CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, depicting changes relative to a reference baseline.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot showing the fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax of Dehydro-Aripiprazole. The plot compares groups based on CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment, with fold changes relative to a reference group.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the changes in AUC and Cmax relative to reference without interacting drugs. The graph compares effects of various inhibitors, inducers, and other drugs like ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam on aripiprazole levels, with fold change values plotted on the x-axis.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of Aripiprazole, showing its molecular framework including chlorine-substituted aromatic rings, piperazine ring, and quinolinone component.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The x-axis is labeled 'Days from Randomization' with time points up to 182 days. The y-axis indicates the proportion with relapse from 0 to 1. The graph includes the number of subjects at risk below the x-axis for different time points for each group. Aripiprazole data is represented by a blue solid line, and placebo by a red dashed line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.